<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-126762</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hemophagocytic syndrome as the initial manifestation of systemic lupus erythematosus</dc:title>
<dc:description xml:lang="en">Introduction: Hemophagocytic syndrome (HS) occurs in autoimmune diseases and belongs o the hemophagocytic lymphohistiocytosis group of diseases. This paper describes the features of 2 patients with systemic lupus erythematosus (SLE) who presented HS as the initial clinical manifestation. Clinical observations: Both patients had prolonged fever not associated to an infectious process and did not respond to broad-spectrum antibiotics. Discussion: The diagnosis of HS secondary to SLE is complicated, because it has some features in common, but HS is characterized by hyperferritinemia, hipofibrinogemia, hypertriglyceridemia and a decrease in the erythrocyte sedimentation rate, unlike SLE. HS treatment when associated to SLE is not well established, but steroids and/or immunoglobulins are effective as the initial treatment, and in refractory cases, cyclosporine or cyclophosphamide may be associated. Conclusions: HS can be the initial manifestation of SLE and should be suspected in patients with organ enlargement, cytopenias, clotting disorders, liver disorders and prolonged fever unresponsive to antibiotics. Anakinra may be a treatment option in adult HS associated to SLE (AU)</dc:description>
<dc:creator>Belzunegui Otano, Joaquín</dc:creator>
<dc:creator>Aldasoro Cáceres, Vicente</dc:creator>
<dc:creator>Uriarte Ecenarro, Miren</dc:creator>
<dc:creator>Egües Dubuc, César Antonio</dc:creator>
<dc:creator>Meneses Villalba, Carlos</dc:creator>
<dc:creator>Hernando Rubio, Iñaki</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. El síndrome hemofagocítico (SH) se produce en enfermedades autoinmunes y pertenece al grupo de enfermedades linfohistiocitosis hemofagocítica. El presente trabajo describe las características de 2 pacientes con lupus eritematoso sistemico (LES) que comenzaron con SH. Observaciones clínicas. Ambos pacientes presentaron fiebre prolongada no asociada a proceso infeccioso y que no respondía a antibióticos. Discusión. El diagnóstico de SH secundario a LES es complicado, ya que presentan características comunes; sin embargo, el SH presenta hiperferritinemia, hipofibrinogenemia, hipertrigliceridemia y descenso de la velocidad de sedimentación globular a diferencia del LES. El tratamiento no está bien establecido, pero los corticoides y/o inmunoglobulinas son efectivos en el tratamiento inicial, y en casos refractarios la ciclosporina o la ciclofosfamida se pueden asociar. Conclusiones. El SH puede ser la manifestación inicial del LES y debe sospecharse en pacientes con organomegalias, citopenias, trastornos en la coagulación, alteraciones hepáticas y fiebre prolongada que no responde a antibióticos. Anakinra puede ser una opción de tratamiento en el SH secundario al LES adulto (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);10(5): 321-324, sept.-oct. 2014. tab</dc:source>
<dc:identifier>ibc-126762</dc:identifier>
<dc:title xml:lang="es">Síndrome hemofagocítico como manifestación clínica inicial del lupus eritematoso sistémico</dc:title>
<dc:subject>^d1805^s22012</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d1805^s22016</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d13546^s22012</dc:subject>
<dc:subject>^d22210^s22073</dc:subject>
<dc:subject>^d3544^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50506^s22016</dc:subject>
<dc:subject>^d8356^s22012</dc:subject>
<dc:subject>^d1807</dc:subject>
<dc:subject>^d50506^s22057</dc:subject>
<dc:subject>^d50506^s22012</dc:subject>
<dc:subject>^d8356^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d3540^s22073</dc:subject>
<dc:subject>^d5444^s22012</dc:subject>
<dc:subject>^d25525^s22045</dc:subject>
<dc:subject>^d13546^s22016</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d5444^s22027</dc:subject>
<dc:type>article</dc:type>
<dc:date>201410</dc:date>
</metadata>
</record>
</ibecs-document>
